Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listOclacitinib

Oclacitinib

  • CAS NO.:1208319-26-9
  • Empirical Formula: C15H23N5O2S
  • Molecular Weight: 337.44
  • MDL number: MFCD25976611
  • EINECS: 950-980-7
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Oclacitinib Structural

What is Oclacitinib?

Description

Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens[1-4].

The Uses of Oclacitinib

Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.

Biological Activity

janus kinase (jak) enzymes are involved in cell signaling pathways activated by cytokines dysregulated in allergy. pf-03394197 (oclacitinib) is a novel janus kinase inhibitor.

in vitro

pf-03394197 inhibited jak family members by 50% at concentrations ranging from 10 to 99 nm and did not inhibit a panel of 38 non-jak kinases. pf-03394197 was most potent at inhibiting jak1. pf-03394197 also inhibited the function of jak1-dependent cytokines involved in allergy and inflammation as well as pruritus. pf-03394197 had minimal effects on cytokines which did not activate the jak1 enzyme in cells [1].

in vivo

pf-03394197 administered orally at a dose of 0.4–0.6 mg/kg twice daily was safe and efficacious in controlling the pruritus associated with allergic dermatitis. pf-03394197 provided itch relief within 24 h that persisted through the treatment period, with over 70% of the treated dogs achieving a >50% reduction in pruritus by day 7 [2].

References

[1] Xin P, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology, 2020; 80: 549-56.
[2] Kalantari Y, et al. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders. International Immunopharmacology, 2022; 110: 108923.[3] Erickson S, et al. New and emerging treatments for inflammatory itch. Annals of Allergy, Asthma Immunology, 2020; 126: 13-20.
[4] Xu P, et al. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. European Journal of Medicinal Chemistry, 2020; 129: 112155.

Properties of Oclacitinib

Melting point: 226-228°C
Density  1.316±0.06 g/cm3(Predicted)
vapor pressure  0Pa at 20-25℃
storage temp.  Refrigerator, Under inert atmosphere
solubility  DMSO (Slightly), Methanol (Slightly, Sonicated)
form  Solid
pka 11.59±0.40(Predicted)
color  Off-White to Pale Beige
InChI InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-

Safety information for Oclacitinib

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H317:Sensitisation, Skin
Precautionary Statement Codes P280:Wear protective gloves/protective clothing/eye protection/face protection.

Computed Descriptors for Oclacitinib

InChIKey HJWLJNBZVZDLAQ-HAQNSBGRSA-N
SMILES [C@@H]1(CS(NC)(=O)=O)CC[C@@H](N(C)C2N=CN=C3NC=CC3=2)CC1

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.